Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M. Kirkwood, Georgina V. Long, Federico Campigotto et al.|Nature Medicine|2023Cited by 208
Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)Georgina V. Long, John M. Kirkwood, Michele Del Vecchio et al.|SKIN The Journal of Cutaneous Medicine|2023Cited by 25
Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre StudyL. Vitek, G. Quéreux, Thomas Goronflot et al.|Acta Dermato Venereologica|2024Cited by 9
Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare databaseLaurent Mortier, Philippe Saïag, Astrid Blom et al.|European Journal of Cancer|2024Cited by 8
Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.A. Blom Fily, Philippe Saïag, Laurent Mortier et al.|Journal of Clinical Oncology|2023Cited by 3